Vaxart Granted Extension by Nasdaq to Regain Compliance
(VAXR) - Company must regain compliance with the Nasdaq Bid Price Rule on or before the October 17, 2025 deadline -
How does this compliance situation compare to similar cases among peer biotech companies and what could it mean for long‑term investor confidence?
What specific measures is Vaxart implementing to meet the Nasdaq Bid Price Rule by the Oct 17, 2025 deadline?
How will the extension affect Vaxart's liquidity and short‑term price movement?
3 days ago